Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 9/20 | 0.56 |
| ▸ | GAA | P10253 | 9/20 | 0.56 |
| ▸ | SI | P14410 | 9/20 | 0.56 |
| ▸ | MGAM2 | Q2M2H8 | 9/20 | 0.56 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | HAT1 | O14929 | 1/20 | 0.37 |
| ▸ | EP300 | Q09472 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | SNCA | P37840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6693201 | 0.93 | GABRA1 (0.50) | MGAMGAASIMGAM2GABRA1 | |
| SCHEMBL6701522 | 0.91 | MGAM (0.45) | MGAMGAASIMGAM2GABRA1 | |
| SCHEMBL6831792 | 0.90 | MGAM (0.53) | MGAMGAASIMGAM2GABRA1 | |
| SCHEMBL23745539 | 0.87 | MGAM (0.72) | MGAMGAASIMGAM2PKM | |
| SCHEMBL6694223 | 0.86 | MGAM (0.46) | MGAMGAASIMGAM2GABRA1 | |
| SCHEMBL6692805 | 0.86 | MGAM (0.51) | MGAMGAASIMGAM2GABRA1 | |
| SCHEMBL6695205 | 0.86 | GAA (0.57) | MGAMGAASIMGAM2PKM | |
| SCHEMBL6694206 | 0.86 | MGAM (0.55) | MGAMGAASIMGAM2GABRA1 | |
| SCHEMBL6698257 | 0.85 | GABRA1 (0.48) | MGAMGAASIMGAM2GABRA1 | |
| SCHEMBL6693172 | 0.85 | GABRA1 (0.58) | MGAMGAASIMGAM2GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138284-A1 | Indol-3-yl derivatives | WIESNER MATTHIAS | 2004-07-15 | — | — | US | disclosed |
| US-6743810-B2 | INTEGRIN INHIBITORS; TUMORS, OSTEOPOROSIS, OSTEOLYTIC DISEASES, SUPPRESSING ANGIOGENESIS, ANTITHROMBOTIC | MERCK PATENT GMBH (DE) | 2004-06-01 | — | — | US | disclosed |
| US-20030045728-A1 | Liberating 3-substituted indole compound from one of its functional derivatives by treatment with a solvolyzing or hydrogenating agent, amidation, saponification, alkylation or acylation, or salt formation | MERCK PATENT GMBH (DE) | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045728-A1 | Liberating 3-substituted indole compound from one of its functional derivatives by treatment with a solvolyzing or hydrogenating agent, amidation, saponification, alkylation or acylation, or salt formation | IGF1R, IDO1, ITGB3 | MGAM 811/4885GAA 3469/4885SI 121/4885 |
| US-20040138284-A1 | Indol-3-yl derivatives | ITGB3, ITGB1, IGF1R | MGAM 1542/4885GAA 3882/4885SI 918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.